STOCK TITAN

Nexalin Technology Warrant (NXLIW) Stock News, Aug 2023-Mar 2024

NXLIW

Nexalin Technology, Inc. develops non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology for brain-health and mental-health indications. Company news centers on clinical evidence for its neurostimulation platform, including peer-reviewed studies involving insomnia, depression-related symptoms, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.

Updates also cover the HALO™ Clarity headset, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA De Novo strategy, international regulatory activity, and public-company events affecting Nexalin securities.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.00%
Tags
none
-
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none

FAQ

What is the current stock price of Nexalin Technology Warrant (NXLIW)?

Nexalin Technology Warrant (NXLIW) last closed at $0.0138.